TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Optimal debulking rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of enzyme replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of enzyme replacement therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Local Recurrence Rate
Endpoint domain: Mortality/survival
Primary endpoint: 1 Year Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Insulin secretion response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients completing deprescribing and/or medication optimization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Abductor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall Survival at 2 Months
Endpoint domain: Mortality/survival
Primary endpoint: level of activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of ICU admissions receiving albumin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful weaning off NCPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye movement and vestibulo-ocular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Antiretroviral Therapy Per Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to Antiretroviral Therapy Per MEMS Caps
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Depressive Symptoms Per Edinburgh Postnatal Depression Scale (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Depressive Symptoms Per MINI - Meeting Criteria for MDD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Global Response Assessment (GRA) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total urine excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total feces excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for endotracheal intubation within 48 hours of admission
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Activation measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients Achieving >= 35% Reduction in Spleen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to weaning of oxygen support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oocyte survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tadalafil 5mg AUCt(0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tadalafil 5mg Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate due to SARS-CoV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Percent of SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of SARS-Cov-2 positives and/or bacterial/viral infection with full resolution by 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in levels due to vitamin K supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in activities due to vitamin K supplementation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intraocular Pressure - Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil engraftment/chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Major adverse cardiovascular and cerebral event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health-Related Quality of Life (HRQoL) - General
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-Related Quality of Life (HRQoL) - Disease specific
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antitumour activity as measured by response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of knowledge and skills in anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: continuous abstinence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Vaccinated Participants With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Vaccinated Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Perimetric mean deviation (PMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portal vein blood flow volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Resting Functional brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamine and Glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: times of pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of neoplastic small bowel lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent reduction in glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6 Min Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Oxygen Uptake (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores in rest and coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consumption of opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ECG parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In vitro binding of Imotopes®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytolytic response against Antigen-Presenting Cells (APC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUCtau of EVG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of EVG at Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Comfort of the demand-driven gas delivery mechanism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of the demand-driven gas delivery mechanism
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of eligible patients receiving prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Rate of Feeling Unreality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of bone structure: Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of bone structure: Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Motor UHDRS rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral glucose test OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood lipid profile: cholesterole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of randomisation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of psychometric assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the self-help book
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the telephone-support calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: arterial condition of the upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Juniper Asthma Control Score (ACS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lifetime suicidal events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Definitive cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital mortality or discharge to hospice
Endpoint domain: Mortality/survival
Primary endpoint: Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Utilization profile of pemetrexed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in MDS-UPDRS Tremor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electrolyte levels (Na, K+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cooperation Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Restenosis of the reconstruction zone after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thrombosis of the reconstruction zone after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Progression of atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Need for sedation medications for MRI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Time in Euglycemic Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Photophobia Free at 2 Hours From Time of First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Phonophobia Free at 2 Hours From Time of First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Nausea Free at 2 Hours From Time of First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of alternative treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 3-month objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone formation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation Emergent Signs and Symptoms (DESS) Total Score at the End of First Week of Tapering
Endpoint domain: Adverse events/effects
Primary endpoint: DESS Total Score at End of Second Week of Tapering
Endpoint domain: Adverse events/effects
Primary endpoint: Median Amount of Blood Products Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time between admission and discharge from the emergency room
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: changes on platelet aggregability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) from Time Zero to Infinite (Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from Time of Dose to Last Measurable Concentration (AUC [0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PANSS-EC total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Bruce Treadmill Test (Fitness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patients' Reported Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in infarct size and myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standardized Mini Mental Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mini Nutritional Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life scale in the elderly
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: initial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in baseline characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle mitochondrial ATP production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hypomania symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With At Least 1 Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ratio of SARS-CoV-2 anxiety scale to Beck anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of ipsilateral new white lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-cell variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta-adrenergic induced sweat rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent late loss (LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective Ratings for Lens Handling for Lens Insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Ratings for Lens Handling for Lens Removal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Kidney Injury (AKI) based on RIFLE criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clostridioides difficile Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Allergic reaction due to CTA scan contrast
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shape observation of excrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to analgesic strategy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Fasting Total Ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in Weight From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Insulin Regulation From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Change From Baseline in Mean PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adherence to immunosuppressive medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vascular and valvular calcium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline on the Vineland-II Two-domain Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Achieving Pathological Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Procedures with Increased Screw Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reducing stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreasing burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enhancing amount of meditation practice
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Myocardial injury assessed by Troponin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standard Alcoholic Drinks Per Treatment Period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ultrasound Image Texture Variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia Diagnostic Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Sensitization Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Physical Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Perceived Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attendance to weekly group meetings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Angiogenesis and vasculogenesis evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in circumferential myocardial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aspiration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Arthralgia Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with Seroprotection to Hepatitis B Surface Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers to Hepatitis B Surface Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: American College of Rheumatology Score 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from recruitment to diagnosis of raised blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Hemoglobin A1C (HbA1C) at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Experience an Adverse Event (AE) over 24 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of couples choosing a safer conception strategy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With a Predicted Effect on αVβ6 PET in Lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subject task performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: O2 Desaturation Index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Left Ventricular (LV) Lead Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: acute postsurgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chronic postsurgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal-to-noise Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes